The pilot project VERO – Optimizing Care of Patients Suffering from Rheumatoid Arthritis has been funded as part of the Innovation Fund of the Gemeinsamer Bundesausschuss since 2016.
More and more patients suffering from rheumatoid arthritis benefit from modern, anti-inflammatory drugs. Upon remission, drug doses can be sometimes reduced and occasionally medication can be even discontinued. Within the pilot project VERO, together with our consortium partners Berufsverband Deutscher Rheumatologen e.V., Universität Hamburg, Techniker Krankenkasse and mhplus Betriebskrankenkasse, we want to systematically implement and evaluate a stepwise reduction of anti-inflammatory drugs in a large number of patients. Based on the data from the VERO project, a comprehensive treatment scheme for rheumatoid arthritis will be established in order to provide patients with a customized, personalized therapy. In addition, patient data will be processed for a central data directory which can be used for answering further questions.
Scientific Management: Prof. Dr. med. Georg Schett